Amedeo Amedei

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5649104/publications.pdf

Version: 2024-02-01

194 papers	10,774 citations	34016 52 h-index	37111 96 g-index
197 all docs	197 docs citations	197 times ranked	15816 citing authors

#	Article	IF	Citations
1	The Role of Gut Microbiota Dysbiosis in Gastrointestinal Carcinogenesis. , 2022, , 442-454.		0
2	Visceral sensitivity modulation by faecal microbiota transplantation: the active role of gut bacteria in pain persistence. Pain, 2022, 163, 861-877.	2.0	17
3	Role of microbiome in cancer immunotherapy. , 2022, , 321-352.		1
4	Probiotics and the gut-liver axis. , 2022, , 467-481.		0
5	Effects of viremia and CD4 recovery on gut â€œmicrobiome-immunityâ€•axis in treatment-naÃ¯ve HIV-1-infected patients undergoing antiretroviral therapy. World Journal of Gastroenterology, 2022, 28, 635-652.	1.4	6
6	Machine learning for analysis of gene expression data in fast- and slow-progressing amyotrophic lateral sclerosis murine models. Biocybernetics and Biomedical Engineering, 2022, 42, 273-284.	3.3	1
7	Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma. World Journal of Hepatology, 2022, 14, 372-385.	0.8	4
8	Performance evaluation of four surrogate Virus Neutralization Tests (sVNTs) in comparison to the in vivo gold standard test. Frontiers in Bioscience, 2022, 27, 074.	0.8	22
9	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clinical Chemistry and Laboratory Medicine, 2022, 60, 934-940.	1.4	5
10	The Potential Role of Peripheral Oxidative Stress on the Neurovascular Unit in Amyotrophic Lateral Sclerosis Pathogenesis: A Preliminary Report from Human and In Vitro Evaluations. Biomedicines, 2022, 10, 691.	1.4	8
11	Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy. Biomedicines, 2022, 10, 819.	1.4	10
12	Chronic Systemic Low-Grade Inflammation and Modern Lifestyle: The Dark Role of Gut Microbiota on Related Diseases with a Focus on COVID-19 Pandemic. Current Medicinal Chemistry, 2022, 29, 5370-5396.	1.2	8
13	Effect of ancient Khorasan wheat on gut microbiota, inflammation, and short-chain fatty acid production in patients with fibromyalgia. World Journal of Gastroenterology, 2022, 28, 1965-1980.	1.4	9
14	Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Biomedicines, 2022, 10, 1227.	1.4	4
15	A comparative study of carbonic anhydrase activity in lymphocytes from colorectal cancer tissues and adjacent healthy counterparts. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1651-1655.	2.5	8
16	Editorial of Special Issue â€œThe Interplay of Microbiome and Immune Response in Health and Diseasesâ€”2nd Editionâ€• International Journal of Molecular Sciences, 2022, 23, 7169.	1.8	0
17	Editorial of Special Issue â€œPharmacomicrobiomics in Non-Communicable Diseaseâ€• Biomedicines, 2022, 10, 1605.	1.4	0
18	Butyrate-Rich Diets Improve Redox Status and Fibrin Lysis in BehÃ§etâ€™s Syndrome. Circulation Research, 2021, 128, 278-280.	2.0	31

#	Article	IF	Citations
19	Evaluation of prognostic factors and clinicopathological patterns of recurrence after curative surgery for colorectal cancer. World Journal of Gastrointestinal Surgery, 2021, 13, 50-75.	0.8	5
20	Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immuneâ€“Microbiota Axis in Ileal Tissue Layers of Patients with Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, 1500-1516.	0.6	19
21	Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat. Journal of Visualized Experiments, 2021, , .	0.2	1
22	Long-Term Follow-Up, Association between CARD15/NOD2 Polymorphisms, and Clinical Disease Behavior in Crohnâ€™s Disease Surgical Patients. Mediators of Inflammation, 2021, 2021, 1-11.	1.4	3
23	Free Fatty Acids Signature in Human Intestinal Disorders: Significant Association between Butyric Acid and Celiac Disease. Nutrients, 2021, 13, 742.	1.7	26
24	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics, 2021, 11, 804.	1.3	5
25	Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach. Journal of Personalized Medicine, 2021, 11, 625.	1.1	20
26	Vaginal Lactobacilli and Vaginal Dysbiosis-Associated Bacteria Differently Affect Cervical Epithelial and Immune Homeostasis and Anti-Viral Defenses. International Journal of Molecular Sciences, 2021, 22, 6487.	1.8	24
27	The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity?. Biomedicines, 2021, 9, 753.	1.4	25
28	Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. Cancers, 2021, 13, 3863.	1.7	6
29	Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews, 2021, 127, 958-978.	2.9	22
30	Microbiota and Myopericarditis: The New Frontier in the Car-Diological Field to Prevent or Treat Inflammatory Cardiomyo-Pathies in COVID-19 Outbreak. Biomedicines, 2021, 9, 1234.	1.4	13
31	Microbiota and viral hepatitis: State of the art of a complex matter. World Journal of Gastroenterology, 2021, 27, 5488-5501.	1.4	9
32	Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance. Biomedicines, 2021, 9, 1338.	1.4	6
33	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules, 2021, 26, 5789.	1.7	23
34	Circulating miRNome profiling data in BehÃ§et's syndrome. Data in Brief, 2021, 38, 107435.	0.5	3
35	Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 38-51.	4.2	58
36	Fecal metabolomic profiles: A comparative study of patients with colorectal cancer vs adenomatous polyps. World Journal of Gastroenterology, 2021, 27, 6430-6441.	1.4	11

#	Article	IF	Citations
37	Duplication of exons 15 and 16 in Matrin-3: a phenotype bridging amyotrophic lateral sclerosis and immune-mediated disorders. Neurological Sciences, 2021, , 1.	0.9	0
38	Supplementation with Lactiplantibacillus plantarum IMC 510 Modifies Microbiota Composition and Prevents Body Weight Gain Induced by Cafeteria Diet in Rats. International Journal of Molecular Sciences, 2021, 22, 11171.	1.8	11
39	Microbiota shaping â€" the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review. World Journal of Gastroenterology, 2021, 27, 6715-6732.	1.4	20
40	Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World Journal of Gastrointestinal Oncology, 2021, 13, 1616-1631.	0.8	5
41	Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?. Mediators of Inflammation, 2021, 2021, 1-13.	1.4	15
42	Multidisciplinary of anti-COVID-19 battle: from immunological weapons to ecological interventions. Frontiers in Bioscience, 2021, 26, 1274.	0.8	0
43	Microbiota and IPF: hidden and detected relationships. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021028.	0.2	7
44	Influence of a 3-month low-calorie Mediterranean diet compared to the vegetarian diet on human gut microbiota and SCFA: the CARDIVEG Study. European Journal of Nutrition, 2020, 59, 2011-2024.	1.8	94
45	Influence of a 3-months low-calorie Mediterranean diet vs. Vegetarian diet on human gut microbiota and SCFA: the CARDIVEG Study. Proceedings of the Nutrition Society, 2020, 79, .	0.4	5
46	Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5521.	1.8	25
47	A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer. IScience, 2020, 23, 101250.	1.9	14
48	Gut microbiota and artificial intelligence approaches: A scoping review. Health and Technology, 2020, 10, 1343-1358.	2.1	16
49	Editorial: Gut Microbiota and Inflammation: Relevance in Cancer and Cardiovascular Disease. Frontiers in Pharmacology, 2020, 11, 613511.	1.6	1
50	Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies. Frontiers in Pharmacology, 2020, 11, 685.	1.6	50
51	Effectiveness of a Khorasan Wheatâ€"Based Replacement on Pain Symptoms and Quality of Life in Patients with Fibromyalgia. Pain Medicine, 2020, 21, 2366-2372.	0.9	7
52	The link â€œCancer and autoimmune diseasesâ€•in the light of microbiota: Evidence of a potential culprit. Immunology Letters, 2020, 222, 12-28.	1.1	14
53	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. International Journal of Molecular Sciences, 2020, 21, 4691.	1.8	40
54	Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer. Frontiers in Immunology, 2020, 11, 573158.	2.2	37

#	Article	IF	Citations
55	Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients. Microbiome, 2020, 8, 140.	4.9	134
56	Not just 'immunity': how the microbiota can reshape our approach to cancer immunotherapy. Immunotherapy, 2020, 12, 407-416.	1.0	6
57	Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: Focus on short and long-term outcomes. World Journal of Gastroenterology, 2020, 26, 2498-2513.	1.4	24
58	Metabolomics profile in gastrointestinal cancers: Update and future perspectives. World Journal of Gastroenterology, 2020, 26, 2514-2532.	1.4	29
59	Exploring the food-gut axis in immunotherapy response of cancer patients. World Journal of Gastroenterology, 2020, 26, 4919-4932.	1.4	17
60	Editorial of Special Issue â€œThe Interplay of Microbiome and Immune Response in Health and Diseasesâ€• International Journal of Molecular Sciences, 2019, 20, 3708.	1.8	5
61	Effect of Probiotics on Oral Candidiasis: A Systematic Review and Meta-Analysis. Nutrients, 2019, 11, 2449.	1.7	33
62	FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 1021.	1.1	48
63	The lung microbiome: clinical and therapeutic implications. Internal and Emergency Medicine, 2019, 14, 1241-1250.	1.0	46
64	Potential therapeutic strategies to target gut microbiota in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 527-529.	0.7	4
65	Circulating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function. Molecules, 2019, 24, 3992.	1.7	54
66	Impact of mediterranean vs vegetarian diets on gut microbiota and short chain fatty acids: The CARDIVEG study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 879.	1.1	0
67	Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. International Journal of Molecular Sciences, 2019, 20, 395.	1.8	317
68	Differential Responses of Colorectal Cancer Cell Lines to Enterococcus faecalisâ€™ Strains Isolated from Healthy Donors and Colorectal Cancer Patients. Journal of Clinical Medicine, 2019, 8, 388.	1.0	28
69	The right place of interleukin-1 inhibitors in the treatment of BehÃ§etâ€™s syndrome: a systematic review. Rheumatology International, 2019, 39, 971-990.	1.5	38
70	Hydrogen Sulfide Effects on the Survival of Lactobacilli with Emphasis on the Development of Inflammatory Bowel Diseases. Biomolecules, 2019, 9, 752.	1.8	35
71	Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-biotics in Inflammatory Bowel Disease. Frontiers in Immunology, 2019, 10, 2754.	2.2	125
72	The Gutâ€“Brain Axis in the Neuropsychological Disease Model of Obesity: A Classical Movie Revised by the Emerging Director â€œMicrobiomeâ€• Nutrients, 2019, 11, 156.	1.7	50

#	Article	IF	Citations
73	Healthy axis: Towards an integrated view of the gut-brain health. World Journal of Gastroenterology, 2019, 25, 3838-3841.	1.4	16
74	Evaluation and comparison of short chain fatty acids composition in gut diseases. World Journal of Gastroenterology, 2019, 25, 5543-5558.	1.4	83
75	Role of diet and gut microbiota on colorectal cancer immunomodulation. World Journal of Gastroenterology, 2018, 25, 151-162.	1.4	103
76	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 2878.	2.2	4
77	Iâ€™ve Gut A Feeling: Microbiota Impacting the Conceptual and Experimental Perspectives of Personalized Medicine. International Journal of Molecular Sciences, 2018, 19, 3756.	1.8	32
78	Gut Inflammatory Diseases, Infection, and Nutrition. Mediators of Inflammation, 2018, 2018, 1-4.	1.4	0
79	The controversial role of Enterococcus faecalis in colorectal cancer. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481878360.	1.4	95
80	The Role of the Microbiota in the Genesis of Gastrointestinal Cancers. Frontiers in Anti-infective Drug Discovery, 2018, , 1-44.	0.6	8
81	Î²2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. Journal of Immunology, 2017, 198, 2640-2648.	0.4	34
82	Treatment of colon cancer cells with 5-fluorouracil can improve the effectiveness of RNA-transfected antitumor dendritic cell vaccine. Oncology Reports, 2017, 38, 561-568.	1.2	8
83	The Different Functional Distribution of â€œNot Effectorâ€•T Cells (Treg/Tnull) in Colorectal Cancer. Frontiers in Immunology, 2017, 8, 1900.	2.2	39
84	Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study. Frontiers in Microbiology, 2017, 8, 2699.	1.5	93
85	Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer. Mediators of Inflammation, 2016, 2016, 1-3.	1.4	18
86	Protein disulfide isomerase A3â€“specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating antiâ€–protein disulfide isomerase A3 autoantibodies. Translational Research, 2016, 171, 17-28.e2.	2.2	27
87	Intra-tumoral IFN-Î³-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clinical Science, 2016, 130, 247-258.	1.8	29
88	Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. International Journal of Oncology, 2016, 49, 393-401.	1.4	23
89	The interplay between the microbiome and the adaptive immune response in cancer development. Therapeutic Advances in Gastroenterology, 2016, 9, 594-605.	1.4	63
90	Gastric cancer and the epoch of immunotherapy approaches. World Journal of Gastroenterology, 2015, 21, 5778-5793.	1.4	80

#	Article	IF	Citations
91	Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology, 2015, 35, S224-S243.	4.3	375
92	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology, 2015, 35, S55-S77.	4.3	95
93	Microparticles: Bridging the Gap between Autoimmunity and Thrombosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 413-422.	1.5	34
94	The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis, 2015, 36, S128-S159.	1.3	40
95	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	1.3	239
96	Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis, 2015, 36, S2-S18.	1.3	55
97	Disruptive chemicals, senescence and immortality. Carcinogenesis, 2015, 36, S19-S37.	1.3	32
98	The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis, 2015, 36, S38-S60.	1.3	32
99	Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis, 2015, 36, S61-S88.	1.3	149
100	Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis, 2015, 36, S89-S110.	1.3	33
101	The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis, 2015, 36, S160-S183.	1.3	97
102	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis, 2015, 36, S184-S202.	1.3	41
103	Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis, 2015, 36, S232-S253.	1.3	168
104	Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 2015, 35, S78-S103.	4.3	535
105	Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology, 2015, 35, S199-S223.	4.3	285
106	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 2015, 35, S5-S24.	4.3	231
107	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Seminars in Cancer Biology, 2015, 35, S25-S54.	4.3	468
108	Thrombosis in vasculitis: from pathogenesis to treatment. Thrombosis Journal, 2015, 13, 15.	0.9	112

#	Article	IF	Citations
109	Therapeutic targeting of replicative immortality. Seminars in Cancer Biology, 2015, 35, S104-S128.	4.3	49
110	A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 2015, 35, S151-S184.	4.3	95
111	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis, 2015, 36, S111-S127.	1.3	43
112	Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?. Carcinogenesis, 2015, 36, S203-S231.	1.3	93
113	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
114	A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies. Thrombosis Research, 2015, 136, 1252-1258.	0.8	23
115	Cancer Immunotherapy: The Share of Cytokines and Chemokines. , 2015, , 315-382.		0
116	Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. Human Vaccines and Immunotherapeutics, 2014, 10, 3354-3368.	1.4	85
117	Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Internal and Emergency Medicine, 2014, 9, 303-309.	1.0	118
118	Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes. Immunology and Cell Biology, 2014, 92, 191-199.	1.0	18
119	Skin CD30+ T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease. Autoimmunity Highlights, 2014, 5, 21-26.	3.9	3
120	Infections, Autoimmunity, and BehÃ§etâ€™s Syndrome: What Liaison?. Rare Diseases of the Immune System, 2014, , 39-51.	0.1	1
121	Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunology, Immunotherapy, 2013, 62, 1249-1260.	2.0	102
122	Cerebrospinal Fluid T-Regulatory Cells Recognize Borrelia Burgdorferi Napa in Chronic Lyme Borreliosis. International Journal of Immunopathology and Pharmacology, 2013, 26, 907-915.	1.0	4
123	What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International, 2013, 2013, 1-14.	0.9	19
124	Orchestration of Inflammation and Adaptive Immunity in Borrelia burgdorferiâ€“Induced Arthritis by Neutrophilâ€Activating Protein A. Arthritis and Rheumatism, 2013, 65, 1232-1242.	6.7	32
125	Helicobacter PyloriHP0175 Promotes the Production of IL-23, IL-6, IL-1Î² and TGF-Î². European Journal of Inflammation, 2013, 11, 261-268.	0.2	7
126	The Use of Cytokines and Chemokines in the Cancer Immunotherapy. Recent Patents on Anti-Cancer Drug Discovery, 2013, 8, 126-142.	0.8	53

#	Article	IF	Citations
127	The use of cytokines and chemokines in the cancer immunotherapy. Recent Patents on Anti-Cancer Drug Discovery, 2013, 8, 126-42.	0.8	20
128	Gastric Cancer and Helicobacter pylori. , 2012, , 25-60.		0
129	Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies. International Journal of Molecular Sciences, 2012, 13, 13438-13460.	1.8	67
130	T Cells in Gastric Cancer: Friends or Foes. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	40
131	New Therapeutic Approaches by Using Microorganism-Derived Compounds. Current Medicinal Chemistry, 2012, 19, 3822-3840.	1.2	22
132	Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1222-1227.	3.3	53
133	Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-Î³R2. Journal of Immunology, 2012, 188, 1011-1018.	0.4	26
134	Vav1Haploinsufficiency in a Common Variable Immunodeficiency Patient with Defective T-Cell Function. International Journal of Immunopathology and Pharmacology, 2012, 25, 811-817.	1.0	18
135	Mucin Depleted Foci, Colonic Preneoplastic Lesions Lacking Muc2, Show Up-Regulation of Tlr2 but Not Bacterial Infiltration. PLoS ONE, 2012, 7, e29918.	1.1	6
136	Potential Role of M. tuberculosis Specific IFN-Î³ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis. PLoS ONE, 2012, 7, e46041.	1.1	58
137	Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood, 2011, 117, 6612-6616.	0.6	55
138	Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood, 2011, 117, 902-914.	0.6	119
139	T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology. Clinical and Developmental Immunology, 2011, 2011, 1-17.	3.3	16
140	Stimulation of TH1 Response by Helicobacter Pylori Neutrophil Activating Protein Decreases the Protective Role of IgE and Eosinophils in Experimental Trichinellosis. International Journal of Immunopathology and Pharmacology, 2011, 24, 895-903.	1.0	7
141	TpF1 fromTreponema pallidumActivates Inflammasome and Promotes the Development of Regulatory T Cells. Journal of Immunology, 2011, 187, 1377-1384.	0.4	44
142	Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-17.	3.0	33
143	Role of immune response in Yersinia pestis infection. Journal of Infection in Developing Countries, 2011, 5, 628-639.	0.5	20
144	T-cell response to bacterial agents. Journal of Infection in Developing Countries, 2011, 5, 640-645.	0.5	54

#	Article	IF	Citations
145	Helicobacter pylori-derived neutrophil-activating protein increases the lifespan of monocytes and neutrophils. Cellular Microbiology, 2010, 12, 754-764.	1.1	18
146	The effect of Helicobacter pylori on asthma and allergy. Journal of Asthma and Allergy, 2010, 3, 139.	1.5	42
147	Î¶â€Crystallin is a bclâ€2 mRNA binding protein involved inbclâ€2overexpression in Tâ€cell acute lymphocytic leukemia. FASEB Journal, 2010, 24, 1852-1865.	0.2	24
148	Targeting IL-23 in human diseases. Expert Opinion on Therapeutic Targets, 2010, 14, 759-774.	1.5	28
149	Impaired TH2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defects. Journal of Allergy and Clinical Immunology, 2010, 126, 671-675.	1.5	11
150	Plant-Derived Recombinant Fl, V, and F1-V Fusion Antigens of Yersinia Pestis Activate Human Cells of the Innate and Adaptive Immune System. International Journal of Immunopathology and Pharmacology, 2009, 22, 133-143.	1.0	22
151	Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunology, Immunotherapy, 2009, 58, 1819-1830.	2.0	29
152	Helicobacter pylori, asthma and allergy. FEMS Immunology and Medical Microbiology, 2009, 56, 1-8.	2.7	53
153	New frontiers in cell-based immunotherapy of cancer. Expert Opinion on Therapeutic Patents, 2009, 19, 623-641.	2.4	11
154	Moraxella Catarrhalis-Specific Th1 Cells in Bal Fluids of Chronic Obstructive Pulmonary Disease Patients. International Journal of Immunopathology and Pharmacology, 2009, 22, 979-990.	1.0	13
155	Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels.. Blood, 2009, 114, 3085-3085.	0.6	1
156	Borrelia burgdorferi NapAâ€“driven Th17 cell inflammation in lyme arthritis. Arthritis and Rheumatism, 2008, 58, 3609-3617.	6.7	93
157	The neutrophil-activating protein ofHelicobacter pyloridown-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cellular Microbiology, 2008, 10, 2355-2363.	1.1	100
158	Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. Journal of Allergy and Clinical Immunology, 2008, 122, 908-913.e5.	1.5	46
159	Identification of a Posttranslational Mechanism for the Regulation of hERG1 K⁺ Channel Expression and hERG1 Current Density in Tumor Cells. Molecular and Cellular Biology, 2008, 28, 5043-5060.	1.1	54
160	The Increase of Endothelial Progenitor Cells in the Peripheral Blood: A New Parameter for Detecting Onset and Severity of Sepsis. International Journal of Immunopathology and Pharmacology, 2008, 21, 697-705.	1.0	43
161	Interfering with chemokines and chemokine receptors as potential new therapeutic strategies. Expert Opinion on Therapeutic Patents, 2008, 18, 309-325.	2.4	9
162	A Macromolecular Signaling Complex Formed by CXCR4, VLA4 and hERG1 K+ Channels Mediates Bone Marrow-Induced Chemo-Resistance in Childhood Acute Lymphoblastic Leukemias: Shortcoming Effects of hERG1 Channels Inhibitors.. Blood, 2008, 112, 1629-1629.	0.6	0

#	Article	IF	Citations
163	Human Gastric Epithelium Produces IL-4 and IL-4Î´2 Isoform Only upon Helicobacter Pylori Infection. International Journal of Immunopathology and Pharmacology, 2007, 20, 809-818.	1.0	12
164	The neutrophil-activating protein ofHelicobacter pylori(HP-NAP) as an immune modulating agent. FEMS Immunology and Medical Microbiology, 2007, 50, 157-164.	2.7	88
165	The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. Journal of Clinical Investigation, 2006, 116, 1092-1101.	3.9	280
166	IFN-Î³-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes and Infection, 2005, 7, 1-8.	1.0	224
167	Helicobacter pylori, T cells and cytokines: the Ã¢Â€Âœdangerous liaisonsÃ¢Â€Â• FEMS Immunology and Medical Microbiology, 2005, 44, 113-119.	2.7	90
168	Human 60-kDa Heat Shock Protein Is a Target Autoantigen of T Cells Derived from Atherosclerotic Plaques. Journal of Immunology, 2005, 174, 6509-6517.	0.4	112
169	The Story So Far:Helicobacter Pyloriand Gastric Autoimmunity. International Reviews of Immunology, 2005, 24, 63-91.	1.5	59
170	Molecular Specificity and Functional Properties of Autoreactive T-Cell Response in Human Gastric Autoimmunity. International Reviews of Immunology, 2005, 24, 111-122.	1.5	16
171	Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood, 2005, 106, 626-634.	0.6	59
172	Helicobacter pylori and gastric autoimmunity. Microbes and Infection, 2004, 6, 1395-1401.	1.0	28
173	Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends in Molecular Medicine, 2004, 10, 316-323.	3.5	137
174	Helicobacter Pylori Infection and Gastric Autoimmunity: Coincidence or Cause-Effect Relationship?. , 2004, , 345-362.		1
175	Characterization of H+,K+-ATPase Tâ€„cell epitopes in human autoimmune gastritis. European Journal of Immunology, 2003, 33, 539-545.	1.6	29
176	Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes and Infection, 2003, 5, 723-730.	1.0	48
177	The Helicobacter pylori Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms. Journal of Experimental Medicine, 2003, 198, 1887-1897.	4.2	274
178	T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6658-6663.	3.3	143
179	Molecular Mimicry between Helicobacter pylori Antigens and H+,K+â€“Adenosine Triphosphatase in Human Gastric Autoimmunity. Journal of Experimental Medicine, 2003, 198, 1147-1156.	4.2	228
180	Helicobacter pylori cag Pathogenicity Island Is Associated with Reduced Expression of Interleukin-4 (IL-4) mRNA and Modulation of the IL-4Î´2 mRNA Isoform in Human Gastric Mucosa. Infection and Immunity, 2003, 71, 6664-6667.	1.0	22

#	Article	IF	Citations
181	Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. European Journal of Immunology, 2002, 32, 1605.	1.6	191
182	H+,K+-ATPase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology, 2001, 120, 377-386.	0.6	147
183	Neonatal bacillus Calmette-GuÃ©rin vaccination induces adult-like IFN-Î³ production by CD4+ T lymphocytes. European Journal of Immunology, 2001, 31, 1531-1535.	1.6	187
184	Preferential Th1 profile of T helper cell responses in X-linked (Brutonâ€²s) agammaglobulinemia. European Journal of Immunology, 2001, 31, 1927-1934.	1.6	40
185	Polarization of PPD-Specific T-Cell Response of Patients with Tuberculosis from Th0 to Th1 Profile after Successful Antimycobacterial Therapy orIn VitroConditioning with Interferon- Î± or Interleukin-12. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 187-194.	1.4	58
186	Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects. European Journal of Immunology, 2000, 30, 2632-2638.	1.6	55
187	Usefulness of 13C-Urea Breath Test in the Diagnosis of Gastric Helicobacter Pylori Infection. International Journal of Immunopathology and Pharmacology, 2000, 13, 27-30.	1.0	8
188	Impaired T-cell regulation of B-cell growth in Helicobacter pyloriâ€“related gastric low-grade MALT lymphoma. Gastroenterology, 1999, 117, 1105-1112.	0.6	100
189	Phenotype and Cytokine Profile ofSchistosoma mansoniSpecific T Cell Lines and Clones Derived from Schistosomiasis Patients with Distinct Clinical Forms. Clinical Immunology, 1999, 91, 338-344.	1.4	14
190	In vivo relevance of CD30 in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 1063-1070.	2.7	37
191	Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney International, 1997, 51, 1876-1884.	2.6	106
192	Different cytokine profile and antigen-specificity repertoire inHelicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. European Journal of Immunology, 1997, 27, 1751-1755.	1.6	207
193	Gastrointestinal Status and Microbiota Shaping in Amyotrophic Lateral Sclerosis: A New Frontier for Targeting?. , 0, , 141-158.		2
194	Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons. , 0, , 473-510.		0